AngioDynamics (ANGO) Q2 2026: MedTech Mix Hits 45% of Sales, Accelerating Margin Expansion
AngioDynamics’ Q2 showcased a decisive shift toward higher-margin MedTech, now comprising 45% of revenue, driving both top-line growth and improved profitability. MedTech’s outperformance, regulatory catalysts in thrombectomy, and NanoKnife’s prostate momentum signal a business increasingly leveraging innovation and portfolio discipline. Leadership transition and manufacturing optimization set the stage for a pivotal year as the company raises guidance and deepens its MedTech focus.
Summary
- MedTech Mix Shift: High-margin platforms now drive nearly half of revenue, fueling margin gains and growth.
- Regulatory and Clinical Catalysts: Thrombectomy and NanoKnife segments benefit from new clearances and CPT code tailwinds.
- Leadership Transition: CEO succession process underway as strategic focus intensifies on innovation and execution.
Performance Analysis
AngioDynamics delivered 8.8% revenue growth in Q2 2026, with MedTech segment sales up 13% and MedDevice up 5.6%. The MedTech segment, now 45% of total sales (up from 43% a year ago), is clearly becoming the company’s growth engine. Arion, atherectomy platform, continued its streak with 18 consecutive quarters of double-digit growth, now representing $16.3 million in revenue, up 18.6%. Mechanical thrombectomy, driven by AlphaVac, posted 3.9% growth despite a tough comp for AngioVac, which was down 7.5% YoY but up 11.2% year-to-date.
Gross margin expanded to 56.4%, up 170 basis points YoY, propelled by the MedTech mix and accelerated manufacturing cost savings. Adjusted EBITDA nearly doubled, with positive cash flow generation of $4.7 million, aided by a $1.4 million contribution from a France distribution deal. The company raised full-year revenue and EBITDA guidance, reflecting confidence in sustained execution.
- MedTech Outperformance: Now 45% of revenue, MedTech’s momentum is reshaping AngioDynamics’ margin profile and growth trajectory.
- Margin Expansion: Cost actions and product mix drove significant YoY margin improvement, with additional upside from manufacturing transfer initiatives.
- International Leverage: CE mark for Arion and France channel deal highlight early success in expanding global reach.
The quarter showed AngioDynamics’ ability to simultaneously drive growth, margin, and cash flow, validating the portfolio shift and operational discipline.
Executive Commentary
"These results prove that we can drive both revenue growth and profitability simultaneously. Based on our strong performance, we are raising our full-year guidance for both revenue and adjusted EBITDA."
Jim Clemmer, President and Chief Executive Officer
"Our gross margin for the second quarter of FY26 was 56.4%, a 170 basis point increase from the second quarter of fiscal year 2025. The early year improvement was driven by continued product mix shift towards MedTech sales, accelerated benefits from our manufacturing transfer initiatives, and the sales channel transaction in France."
Steve Trowbridge, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. MedTech as Core Value Driver
The MedTech segment’s rise to 45% of total revenue marks a structural shift in AngioDynamics’ business model, with higher growth and margin profiles than legacy MedDevice. This segment is anchored by Arion, mechanical thrombectomy, and NanoKnife, each with distinct growth vectors and regulatory catalysts. Management is intentionally pushing product mix and commercial focus toward these platforms, accelerating both revenue and profitability.
2. Regulatory and Clinical Momentum
Three major regulatory milestones in mechanical thrombectomy (IDE approvals for APEX Return and PAVE studies, plus 510(k) clearance for AlphaVac F1885) expand addressable markets and clinical applications. The new CPT code for NanoKnife prostate procedures, effective January 1, is expected to drive gradual adoption, with strong physician interest and growing procedure volumes already evident. These catalysts position AngioDynamics to capture share in underpenetrated and emerging markets.
3. Operational Leverage and Cost Actions
Manufacturing transfer initiatives accelerated cost savings, contributing to gross margin expansion ahead of schedule. The company is shifting production to lower-cost facilities and optimizing indirect labor, resulting in sustainable leverage. SG&A and R&D investment remain disciplined, with R&D targeted at 10% of sales to support long-term MedTech innovation.
4. Portfolio and Channel Discipline
Active portfolio management—including divestitures and targeted international distribution deals—has sharpened strategic focus and improved capital allocation. The France distribution transaction not only boosted EBITDA but also positions AngioDynamics for scalable international growth, especially in MedTech platforms.
5. Leadership Transition and Succession
CEO Jim Clemmer’s planned retirement initiates a formal search for new leadership, with a focus on continuity and strategic momentum. The board’s approach signals a commitment to sustaining innovation and operational execution through the transition, a critical factor as the company enters a new phase of growth.
Key Considerations
This quarter marks an inflection point as AngioDynamics’ MedTech platforms increasingly define the company’s growth and profitability profile. Execution on regulatory, operational, and portfolio fronts is translating into tangible financial results and improved guidance.
Key Considerations:
- MedTech Revenue Mix: Sustained mix shift is essential for margin expansion and valuation re-rating.
- Regulatory Execution: Timely IDE and 510(k) clearances are unlocking new clinical and commercial opportunities.
- NanoKnife Prostate Adoption: Early tailwinds from CPT code activation suggest a multi-year growth driver, but ramp will be gradual.
- Manufacturing Optimization: Cost savings from production transfer are largely realized, with some structural under-absorption expected in the back half.
- Leadership Change: CEO transition introduces uncertainty, but process is structured to ensure operational continuity.
Risks
Risks include execution on MedTech adoption, particularly in international and new clinical applications, as well as potential delays in regulatory or reimbursement tailwinds. Manufacturing transitions may cause short-term margin volatility due to under-absorption. The CEO transition, while planned, introduces some leadership risk during a period of strategic transformation. Tariff expenses remain a headwind, with $4-6 million expected for the year.
Forward Outlook
For Q3 2026, AngioDynamics expects:
- Continued MedTech revenue growth, though MedDevice growth will moderate
- Gross margin to remain in the 53.5% to 55.5% range, reflecting structural cost actions and mix shift
For full-year 2026, management raised guidance:
- Net sales of $312 to $314 million (previously $308 to $313 million)
- Adjusted EBITDA of $8 million to $10 million (previously $6 million to $10 million)
- Gross margin guidance unchanged, with tariff impact fully included
Management noted adjusted EBITDA will be lower in the back half due to increased R&D and commercial investments, but full-year cash flow remains positive. Leadership emphasized confidence in sustaining profitable growth and innovation-driven expansion.
Takeaways
AngioDynamics’ Q2 2026 results validate its MedTech-centric strategy, with execution across innovation, margin expansion, and portfolio discipline. The business is increasingly defined by its higher-growth, higher-margin segments, regulatory catalysts, and operational agility.
- MedTech Momentum: The mix shift to MedTech is now central to margin and growth, with regulatory and reimbursement catalysts supporting future upside.
- Operational Discipline: Manufacturing optimization and cost actions are delivering on gross margin, with further leverage possible as volume scales.
- Strategic Watchpoint: Investors should monitor MedTech adoption rates, international traction, and execution continuity during the CEO transition.
Conclusion
AngioDynamics’ Q2 marks a clear pivot toward MedTech-driven value creation, with financial and operational results supporting a raised outlook. The company is well positioned for continued growth, though execution on innovation, adoption, and leadership transition will be critical in the coming year.
Industry Read-Through
AngioDynamics’ results highlight the growing premium on high-margin, innovation-driven medtech portfolios in the broader medical device industry. The ability to shift revenue mix, deliver regulatory catalysts, and optimize manufacturing is increasingly a prerequisite for margin expansion and valuation upside. The NanoKnife CPT code win and thrombectomy platform advances also signal rising stakes for clinical evidence and reimbursement as sustainable growth levers. Competitors and investors should watch for similar portfolio discipline and operational agility as industry standards shift toward MedTech-centric models.